- Home
- NTIP vs UBX Comparison
NTIP vs UBX Comparison
Compare NTIP & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- UBX
- Stock Information
- Founded
- NTIP 1990
- UBX 2009
- Country
- NTIP United States
- UBX United States
- Employees
- NTIP N/A
- UBX N/A
- Industry
- NTIP Multi-Sector Companies
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- UBX Health Care
- Exchange
- NTIP Nasdaq
- UBX Nasdaq
- Market Cap
- NTIP 32.9M
- UBX 36.9M
- IPO Year
- NTIP 1998
- UBX 2018
- Fundamental
- Price
- NTIP $1.36
- UBX $1.79
- Analyst Decision
- NTIP
- UBX Strong Buy
- Analyst Count
- NTIP 0
- UBX 3
- Target Price
- NTIP N/A
- UBX $7.33
- AVG Volume (30 Days)
- NTIP 18.4K
- UBX 122.4K
- Earning Date
- NTIP 02-28-2025
- UBX 03-07-2025
- Dividend Yield
- NTIP 7.30%
- UBX N/A
- EPS Growth
- NTIP N/A
- UBX N/A
- EPS
- NTIP N/A
- UBX N/A
- Revenue
- NTIP $100,000.00
- UBX N/A
- Revenue This Year
- NTIP N/A
- UBX N/A
- Revenue Next Year
- NTIP N/A
- UBX N/A
- P/E Ratio
- NTIP N/A
- UBX N/A
- Revenue Growth
- NTIP N/A
- UBX N/A
- 52 Week Low
- NTIP $1.22
- UBX $0.94
- 52 Week High
- NTIP $2.15
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- NTIP 47.21
- UBX 49.56
- Support Level
- NTIP $1.33
- UBX $1.53
- Resistance Level
- NTIP $1.38
- UBX $1.98
- Average True Range (ATR)
- NTIP 0.03
- UBX 0.21
- MACD
- NTIP -0.00
- UBX -0.00
- Stochastic Oscillator
- NTIP 37.50
- UBX 49.21
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.